A Phase 1 Multiple-Ascending-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB078 Administered Intrathecally to Adults With C9ORF72-Associated Amyotrophic Lateral Sclerosis
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2019
Price : $35 *
At a glance
- Drugs BIIB-078 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Sponsors Biogen
- 27 Nov 2019 Planned number of patients changed from 80 to 90.
- 27 Nov 2019 Planned End Date changed from 27 Sep 2021 to 28 Sep 2021.
- 27 Nov 2019 Planned primary completion date changed from 27 Sep 2021 to 28 Sep 2021.